Post–partum haemorrhage (PPH) is a leading cause of maternal mortality, accounting for about 100 000 maternal deaths every year. Almost all (99%) of the deaths are in low and middle income countries and most of the deaths occur in the immediate post-partum period. There are known effective treatments for preventing severe bleeding after childbirth and it is essential to ensure that all pregnant women have access to these. However, even with these treatments, many women will develop severe post-partum bleeding and there is an urgent need for a safe and effective treatment that is inexpensive and easy to administer in a range of different health care settings.

This editorial invites the participation of obstetricians, midwives and nurses from around the world to join the WOMAN (World Maternal Antifibrinolytic) trial—an international collaborative effort to identify such a treatment.

Tranexamic acid (TXA) is an anti-fibrinolytic agent that inhibits clot breakdown by blocking the lysine binding sites on plasminogen molecules. TXA is not a new drug and has been used for many years to treat menorrhagia and dental extraction in people with haemophilia. More recently, it has been used to reduce bleeding in elective surgical patients. Although there are many on-going trials of TXA in elective surgery, the accumulated evidence already shows that TXA reduces bleeding. A recently updated systematic review of randomized trials of TXA in elective surgery found 53 randomized trials, including a total of 3836 participants. TXA reduces blood transfusion by about one-third [relative risk (RR) = 0.61 (95% CI 0.54 to 0.70)] with a trend towards reduced mortality that was not statistically significant [RR = 0.61 (95% CI 0.32–1.12)].

New results from the CRASH-2 trial of TXA in bleeding trauma patients provide grounds for optimism that TXA might reduce mortality and the need for hysterectomy in women with PPH (http://www.thelancet.com/crash-2). In the CRASH-2 trial, 20 211 adults with traumatic haemorrhage were randomized to either TXA (loading dose 1g over 10 min followed by infusion of 1g over 8h) or matching placebo, with 99.6% follow-up. The risk of death due to bleeding was significantly reduced with TXA [489 (4.9%) TXA versus 574 (5.7%) placebo of 10 067 patients; RR 0.85 (95% CI 0.76–0.96); 2P = 0.008]. Importantly, there was no increase in fatal or non-fatal vascular occlusive events [168 (1.7%) TXA versus 201 (2.0%) placebo; RR 0.84 (95% CI 0.68–1.0); 2P = 0.08]. All-cause mortality was also significantly reduced with TXA [1463 (14.5%) TXA versus 1613 (16.0%) placebo; RR = 0.91 (95% CI 0.85–0.97); 2P = 0.004]. The large numbers of patients studied from hospitals in high-, middle- and low-income countries, help these results to be generalized widely. As TXA is inexpensive and easy to administer, it can be easily added to the normal medical and surgical management of trauma patients in hospitals worldwide.

The knowledge that TXA safely reduces the mortality in traumatic haemorrhage raises the possibility that it might also be effective in PPH. To date, there have been only a few small trials of TXA in post-partum bleeding, including in total less than 500 women. Although there was a significant reduction in post-partum blood loss in women treated with TXA, the quality of the trials was poor. None had well-concealed treatment allocation and even in aggregate they were too small to assess the effects of TXA on mortality, hysterectomy and thrombotic side effects. The recently updated PPH treatment guidelines prepared by the World Health Organization (WHO) state that TXA may be used if other measures fail, but points out that the evidence base is poor and calls for further clinical trials of TXA in PPH.

The WOMAN trial, coordinated by the London School of Hygiene & Tropical Medicine (University of London), has been launched in response to this important clinical uncertainty. WOMAN is a pragmatic, randomized, double-blind, placebo-controlled trial among women with a clinical diagnosis of post-partum haemorrhage that will determine reliably the effect of the early administration of TXA on death.
hysterectomy and other morbidities (surgical interventions, blood transfusion and risk of non-fatal vascular events), in woman with PPH. The trial is already recruiting eligible women in hospitals in Africa and Europe, but many new collaborating centres are needed in order to reach the target sample size of 15,000 women.

Full details of the protocol and how to join the trial are available on the trial web site (www.thewomantrial.lshtm.ac.uk), or by e-mailing TheWomanTrial@lshtm.ac.uk. The success of the WOMAN Trial depends on the collaboration of midwives, nurses and doctors from hospitals all around the world. The hope is that by working together we might identify a safe and effective treatment that could save the lives of tens of thousands of new mothers.

Funding

LSHTM is funding the run-in costs for this trial and up to 2000 patients’ recruitment. Full funding is being sought from public funding organisations. Pfizer, the manufacturer of tranexamic acid, have provided the funding for the trial drug and placebo used for this trial. The design and management of the study are entirely independent of the manufacturers of tranexamic acid, which is not a new product.

References